Equity Profile

ADMA

ADMA Biologics, Inc.

Health CareBiotechnology$1.8B

May6Wed

Post-Earnings Recap

ReportedQ1-2026After Close4:05 PM EDT

ADMA Biologics Misses on Revenue, Stock Down 1.66%

Metric	Actual	Expected	Surprise
EPS	$0.19	$0.20	—
Revenue	—	$140M	—

management commentary, guidance changes, and full analysis available with Pro.

ADMA Biologics Misses on Revenue, Stock Down 1.66%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$0.19	$0.20	—
Revenue	—	$140M	—

Management Commentary

Tone: Unknown

No transcript is on record for this earnings call, and the analysis is based solely on numerical results.

What It Means

ADMA Biologics reported earnings that fell short of revenue expectations, which may have contributed to the stock's decline of 1.66%. The company did not provide any forward guidance or additional commentary, leaving investors without insights into future performance. The missed revenue target could raise concerns about sales growth and market demand for their products.

Company Snapshot

ADMA Biologics, Inc. is a biotechnology company focused on developing and commercializing specialty biologics for the treatment of immune deficiencies and infectious diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

$0.20

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$140M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

ADMA Biologics, Inc. is a biotechnology company focused on developing and commercializing specialty biologics for the treatment of immune deficiencies and infectious diseases. Operating in the Health Care sector, ADMA is significant for its contributions to the growing field of immunotherapy and the production of high-quality immunoglobulin therapies.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+30.88%

Avg Stock Reaction

+0.95%

Last Quarter Recap

In the last quarter, ADMA reported an EPS of $0.20, meeting expectations. The stock reacted positively, gaining 1.03% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect ADMA to report earnings that meet or slightly exceed the consensus estimates. The market is keenly watching for any signs of growth in revenue and profitability.

Bull Case

If ADMA can demonstrate strong revenue growth and maintain or improve its EPS, it could signal robust demand for its products and lead to a positive stock reaction.

Bear Case

Conversely, if the company fails to meet revenue expectations or shows signs of declining profitability, it could lead to a significant drop in stock price.

Key Metrics to Watch

EPS

$0.20

Earnings per share is a key indicator of the company's profitability and financial health.

Revenue

$140M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will ADMA's revenue exceed the consensus estimate of $140 million?

Revenue growth is crucial for demonstrating market demand and the company's ability to scale its operations.

Can ADMA maintain its EPS at $0.20 or better?

Earnings per share is a direct measure of profitability, and maintaining or exceeding this figure could boost investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate ADMA's ability to leverage recent product developments and market expansion, which could lead to stronger-than-expected revenue growth.

Supporting Evidence

The company's recent performance has shown resilience, with a 71% EPS beat rate historically.

Options pricing suggests a significant move, indicating that traders are anticipating volatility, which could reflect underlying strength.

Insider selling activity could indicate confidence in the company's future prospects despite the recent stock performance.

Key Risk

If revenue comes in significantly above $140 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal as it will indicate whether ADMA can sustain its growth trajectory amid market challenges.

Bull Confirmed If

Revenue growth above $140 million with EPS at or above $0.20 would confirm the bull case.

Bear Confirmed If

Any revenue below $138 million or EPS below $0.20 would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±15.71%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±18.0% while ADMA has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.2%

30d HV

96.3%

Calls (251K)P/C Ratio: 0.10Puts (22K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$318,360.00

21,000 sh

1 insider

Net

$318,360.00

Net selling

Most Active Insiders· 2 open-market trades

President and CEOGrossman Adam S
$318,360.00

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Top holders adding

Institutional

97.01%

of float

Insider

1.85%

of float

Holders

474

institutions

Top Holders· as of Dec 2025

Blackrock Inc.
36,333,325 sh · $409.1M
15.64%
2.0%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If ADMA beats expectations, history suggests a positive stock reaction, averaging a 0.42% increase.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further guidance.

Miss

A miss could lead to a more significant decline, with history suggesting an average drop of 3.59%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on product pipeline developments and their expected market impact.
2Any commentary on competitive pressures and market share.
3Insights into customer demand trends for ADMA's therapies.
4Management's outlook on operational efficiency and cost management.
5Details on any new partnerships or collaborations that could drive growth.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

GRABReported

Grab Holdings Limited

RecapView

May4

GBDCReported

Company Snapshot

ADMA Biologics, Inc. is a biotechnology company focused on developing and commercializing specialty biologics for the treatment of immune deficiencies and infectious diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

$0.20

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$140M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+30.88%

Avg Stock Reaction

+0.95%

Last Quarter Recap

In the last quarter, ADMA reported an EPS of $0.20, meeting expectations. The stock reacted positively, gaining 1.03% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect ADMA to report earnings that meet or slightly exceed the consensus estimates. The market is keenly watching for any signs of growth in revenue and profitability.

Bull Case

If ADMA can demonstrate strong revenue growth and maintain or improve its EPS, it could signal robust demand for its products and lead to a positive stock reaction.

Bear Case

Conversely, if the company fails to meet revenue expectations or shows signs of declining profitability, it could lead to a significant drop in stock price.

Key Metrics to Watch

EPS

$0.20

Earnings per share is a key indicator of the company's profitability and financial health.

Revenue

$140M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will ADMA's revenue exceed the consensus estimate of $140 million?

Revenue growth is crucial for demonstrating market demand and the company's ability to scale its operations.

Can ADMA maintain its EPS at $0.20 or better?

Earnings per share is a direct measure of profitability, and maintaining or exceeding this figure could boost investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate ADMA's ability to leverage recent product developments and market expansion, which could lead to stronger-than-expected revenue growth.

Supporting Evidence

The company's recent performance has shown resilience, with a 71% EPS beat rate historically.

Options pricing suggests a significant move, indicating that traders are anticipating volatility, which could reflect underlying strength.

Insider selling activity could indicate confidence in the company's future prospects despite the recent stock performance.

Key Risk

If revenue comes in significantly above $140 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal as it will indicate whether ADMA can sustain its growth trajectory amid market challenges.

Bull Confirmed If

Revenue growth above $140 million with EPS at or above $0.20 would confirm the bull case.

Bear Confirmed If

Any revenue below $138 million or EPS below $0.20 would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±15.71%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±18.0% while ADMA has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.2%

30d HV

96.3%

Calls (251K)P/C Ratio: 0.10Puts (22K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$318,360.00

21,000 sh

1 insider

Net

$318,360.00

Net selling

Most Active Insiders· 2 open-market trades

President and CEOGrossman Adam S
$318,360.00

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Top holders adding

Institutional

97.01%

of float

Insider

1.85%

of float

Holders

474

institutions

Top Holders· as of Dec 2025

Blackrock Inc.
36,333,325 sh · $409.1M
15.64%
2.0%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If ADMA beats expectations, history suggests a positive stock reaction, averaging a 0.42% increase.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further guidance.

Miss

A miss could lead to a more significant decline, with history suggesting an average drop of 3.59%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on product pipeline developments and their expected market impact.
2Any commentary on competitive pressures and market share.
3Insights into customer demand trends for ADMA's therapies.
4Management's outlook on operational efficiency and cost management.
5Details on any new partnerships or collaborations that could drive growth.